Current treatment status-Undergoing active treatment-Progressive despite several lines of treatment Posts on Medivizor
Navigation Menu

Current treatment status-Undergoing active treatment-Progressive despite several lines of treatment Posts on Medivizor

Evaluating rituximab plus lenalidomide for recurrent or non-responsive indolent non-Hodgkin lymphoma

Posted by on Apr 30, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of rituximab (Rituxan) plus lenalidomide (Revlimid) for patients with recurrent or non-responsive non-Hodgkin’s lymphoma (NHL). This study concluded that lenalidomide was well-tolerated and improved the effectiveness of rituximab in these patients. Some background Follicular...

Read More

Evaluating chemotherapy regimens before stem cell transplantation for patients with non-Hodgkin’s lymphoma

Posted by on Apr 25, 2019 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study evaluated the effectiveness of BEAM chemotherapy versus BUCYVP16 chemotherapy in patients with non-Hodgkin’s lymphoma (NHL) before autologous stem cell transplantation (ASCT). This study concluded that these regimens were similarly safe and effective for these patients before ASCT. Some background For patients with NHL...

Read More

Evaluating long-term outcomes after radiation and stem cell transplantation for recurrent or unresponsive Hodgkin lymphoma

Posted by on Apr 15, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the long-term outcomes of patients with recurrent or non-responsive classical Hodgkin’s lymphoma (cHL) after undergoing radiation, chemotherapy, and autologous stem cell transplantation (autoSCT). This study concluded that total lymphoid irradiation (TLI) therapy before a bone marrow transplant can improve...

Read More

A combination of clarithromycin, pomalidomide and dexamethasone in patients with relapsed/unresponsive multiple myeloma

Posted by on Apr 12, 2019 in Multiple Myeloma | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of a combination of clarithromycin, pomalidomide, and dexamethasone (the ClaPd regime) in patients with relapsed/unresponsive multiple myeloma who had been treated with lenalidomide. This study concluded that this combination is as effective as other currently used...

Read More

New treatment improves tumor response in patients with HER2 positive metastatic colorectal cancer

Posted by on Apr 8, 2019 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effectiveness of pertuzumab (Perjeta) and trastuzumab (Herceptin) in patients with colorectal cancer and HER2 mutation (an abnormal gene). Researchers suggested that this treatment could be a safe option for patients with metastatic (spread to other parts of the body) colorectal cancer (mCRC). Some background...

Read More

The use of brentuximab vedotin before transplant for patients with Hodgkin’s lymphoma

Posted by on Mar 29, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study aimed to compare outcomes for patients with Hodgkin’s lymphoma who received brentuximab vedotin (Adcetris) compared to chemotherapy before a stem cell transplant. This study concluded that patients who received brentuximab vedotin had a better survival. Some background Allogeneic hematopoietic stem cell...

Read More

Comparing conditioning regimens before stem cell transplantation for patients with Hodgkin lymphoma

Posted by on Mar 28, 2019 in Hodgkin's lymphoma | 0 comments

In a nutshell This study evaluated the safety and effectiveness of two chemotherapy regimens before autologous stem cell transplantation (ASCT) for patients with Hodgkin lymphoma (HL). This study concluded that BEAM conditioning before ASCT significantly improved the outcomes of these patients. Some background About 20 – 30% of patients...

Read More

The impact of graft-versus-lymphoma effect on outcomes after reduced intensity conditioned stem cell transplant

Posted by on Mar 26, 2019 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the impact of the graft-versus-lymphoma effect on the outcomes for patients with leukemia/lymphoma who are treated with reduced-intensity conditioning (RIC) with alemtuzumab (Lemtrada) allogeneic hematopoietic stem cell transplant (allo-HSCT).  This study concluded that the graft-versus-lymphoma effect...

Read More

Allogenic hematopoietic stem cell transplant for patients with unresponsive acute myeloid leukemia

Posted by on Mar 20, 2019 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the effectiveness of allogeneic hemopoietic stem cell transplant (alloHSCT) in patients with unresponsive acute myeloid leukemia. This study concluded that alloHSCT is the best treatment option for these patients. Some background Patients with unresponsive acute myeloid leukemia (AML) are those...

Read More

Is entospletinib an effective treatment for relapsed or unresponsive chronic lymphocytic leukemia?

Posted by on Mar 12, 2019 in Leukemia | 0 comments

In a nutshell This study examined if entospletinib can be used as a treatment for relapsed or unresponsive chronic lymphocytic leukemia (CLL). This study concluded entospletinib has disease reducing activity in patients with CLL, where previous treatment has failed. Some background Chronic lymphocytic leukemia (CLL) is a cancer of the bone marrow. It...

Read More

Evaluating carfilzomib plus dexamethasone for relapsed or refractory multiple myeloma

Posted by on Mar 10, 2019 in Multiple Myeloma | 0 comments

In a nutshell This study evaluated the impact of carfilzomib (Kyprolis) and dexamethasone (Decadron) on quality of life for patients with relapsed or refractory (does not respond to treatment) multiple myeloma (MM). This study concluded that patients treated with this combination had a higher quality of life. Some background MM is a...

Read More

Combining ibrutinib and umbralisib to treat relapsed/unresponsive chronic lymphocytic leukemia

Posted by on Feb 28, 2019 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the safety and effectiveness of ibrutinib (Imbruvica) combined with umbralisib for patients with released/unresponsive chronic lymphocytic leukemia (CLL). This study concluded that the combination of umbralisib and ibrutinib is well tolerated and effective in relapsed/unresponsive CLL.  Some background...

Read More